Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells

Mutant p53 proteins result from missense mutations in the TP53 gene, the most mutated in human cancer, and have been described to contribute to cancer initiation and progression. Therapeutic strategies for targeting mutant p53 proteins in cancer cells are limited and have proved unsuitable for clini...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Garrido, Eduardo, Cordani, Marco, Somoza, Álvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703659/
https://www.ncbi.nlm.nih.gov/pubmed/34959348
http://dx.doi.org/10.3390/pharmaceutics13122067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703659/
https://www.ncbi.nlm.nih.gov/pubmed/34959348
http://dx.doi.org/10.3390/pharmaceutics13122067

Ejemplares similares